Related Experiment Videos
Rickets, osteomalacia, and renal osteodystrophy. An update
1Harvard Medical School, Boston, Massachusetts.
The Orthopedic Clinics of North America
|January 1, 1990
Summary
Rickets, osteomalacia, and renal osteodystrophy are bone mineralization disorders caused by calcium or phosphorus deficiency. Advances in understanding vitamin D metabolism and mineral hemostasis allow for effective treatment in children and adults.
Area of Science:
- Bone Metabolism and Mineralization Disorders
- Pediatric and Adult Endocrinology
- Nutritional Deficiencies
Background:
- Rickets, osteomalacia, and renal osteodystrophy are bone mineralization disorders.
- These conditions arise from deficiencies in calcium, phosphorus, or both.
- Diverse mechanisms lead to these diseases, often presenting similarly, necessitating laboratory diagnosis.
Purpose of the Study:
- To review the pathophysiology and clinical presentation of bone mineralization disorders.
- To highlight the diagnostic challenges posed by the stereotyped presentation of rickets, osteomalacia, and renal osteodystrophy.
- To discuss recent advancements in understanding calcium-phosphorus homeostasis and vitamin D metabolism for improved treatment.
Main Methods:
- Review of existing literature on bone mineralization disorders.
- Analysis of the clinical, radiological, and laboratory features of rickets, osteomalacia, and renal osteodystrophy.
- Synthesis of current knowledge on calcium-phosphorus balance and vitamin D metabolism.
Main Results:
- Rickets in children causes long bone deformities and dwarfism due to epiphyseal plate effects.
- In adults, these disorders manifest as osteopenia and pathological fractures.
- Laboratory investigations are crucial for differentiating between various causes of these conditions.
Conclusions:
- Effective treatments are now available for many children and adults with these disorders.
- Improved understanding of vitamin D metabolism and calcium-phosphorus hemostasis underpins therapeutic advancements.
- Early diagnosis and targeted treatment are essential for managing bone mineralization disorders.